James William Rogers Sells 8,712 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 8,712 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $67.57, for a total value of $588,669.84. Following the completion of the transaction, the chief financial officer now owns 221,100 shares of the company’s stock, valued at approximately $14,939,727. This represents a 3.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

James William Rogers also recently made the following trade(s):

• On Monday, December 16th, James William Rogers sold 1,468 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total transaction of $59,057.64.
• On Wednesday, December 11th, James William Rogers sold 83,025 shares of Tempus AI stock. The stock was sold at an average price of $42.30, for a total transaction of $3,511,957.50.

Tempus AI Price Performance

TEM traded up $3.97 during midday trading on Friday, hitting $68.96. The stock had a trading volume of 16,292,734 shares, compared to its average volume of 11,766,354. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business has a fifty day moving average of $44.36 and a 200 day moving average of $48.84.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Wolfe Research started coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently made changes to their positions in the business. First Horizon Advisors Inc. bought a new position in Tempus AI during the 3rd quarter worth approximately $30,000. Geode Capital Management LLC lifted its stake in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at about $67,000. IFP Advisors Inc bought a new stake in Tempus AI during the 4th quarter valued at approximately $76,000. Finally, US Bancorp DE purchased a new stake in Tempus AI in the fourth quarter worth $80,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.